FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968882012> ?p ?o ?g. }

• W1968882012 endingPage "394" @default.
• W1968882012 startingPage "390" @default.
• W1968882012 abstract "Objectives ErbB family members present an attractive target for therapeutic manipulation in bladder cancer. Lapatinib is an oral, small molecule, reversible dual inhibitor of ErbB1 (epidermal growth factor receptor) and ErbB2 (HER2) tyrosine kinases. Cisplatin-based combination chemotherapy has proven benefit in palliating symptoms and prolonging survival in patients with metastatic bladder cancer. In this study, we investigated the potential utility of lapatinib as an adjunct to chemotherapy in human bladder cancer cell lines. We also assessed whether these interactions were schedule dependent and synergistic. Methods We chose two bladder cancer cell lines, one (RT112) with high expression of ErbB1 and ErbB2 and one (J82) with low expression of these receptors. These cell lines were used to determine the growth inhibitory effects of lapatinib and the clinically relevant combination of gemcitabine and cisplatin (GC) chemotherapy. Four different schedules were assessed: GC alone (no lapatinib); lapatinib before and during GC; lapatinib concomitant with GC; and lapatinib after GC. Results Lapatinib reduced cell viability in both cell lines in a dose-dependent fashion. The values for the 50% inhibitory concentration for RT112 and J82 cells after lapatinib were similar. In both cell lines, the addition of lapatinib to GC potentiated the efficacy. The optimal sequence consisted of lapatinib before and during GC. Using this schedule, cooperation was synergistic. Conclusions Our data present evidence that lapatinib cooperates with clinically relevant cytotoxic agents and may have therapeutic utility in the management of chemotherapy-naive metastatic bladder cancer. Lapatinib may also enable reduced-dose chemotherapy, a potential toxicity-sparing strategy. ErbB family members present an attractive target for therapeutic manipulation in bladder cancer. Lapatinib is an oral, small molecule, reversible dual inhibitor of ErbB1 (epidermal growth factor receptor) and ErbB2 (HER2) tyrosine kinases. Cisplatin-based combination chemotherapy has proven benefit in palliating symptoms and prolonging survival in patients with metastatic bladder cancer. In this study, we investigated the potential utility of lapatinib as an adjunct to chemotherapy in human bladder cancer cell lines. We also assessed whether these interactions were schedule dependent and synergistic. We chose two bladder cancer cell lines, one (RT112) with high expression of ErbB1 and ErbB2 and one (J82) with low expression of these receptors. These cell lines were used to determine the growth inhibitory effects of lapatinib and the clinically relevant combination of gemcitabine and cisplatin (GC) chemotherapy. Four different schedules were assessed: GC alone (no lapatinib); lapatinib before and during GC; lapatinib concomitant with GC; and lapatinib after GC. Lapatinib reduced cell viability in both cell lines in a dose-dependent fashion. The values for the 50% inhibitory concentration for RT112 and J82 cells after lapatinib were similar. In both cell lines, the addition of lapatinib to GC potentiated the efficacy. The optimal sequence consisted of lapatinib before and during GC. Using this schedule, cooperation was synergistic. Our data present evidence that lapatinib cooperates with clinically relevant cytotoxic agents and may have therapeutic utility in the management of chemotherapy-naive metastatic bladder cancer. Lapatinib may also enable reduced-dose chemotherapy, a potential toxicity-sparing strategy." @default.
• W1968882012 created "2016-06-24" @default.
• W1968882012 creator A5017033561 @default.
• W1968882012 creator A5037538728 @default.
• W1968882012 creator A5049429003 @default.
• W1968882012 creator A5079096357 @default.
• W1968882012 date "2007-02-01" @default.
• W1968882012 modified "2023-10-16" @default.
• W1968882012 title "Combined Treatment of Bladder Cancer Cell Lines with Lapatinib and Varying Chemotherapy Regimens—Evidence of Schedule-Dependent Synergy" @default.
• W1968882012 cites W1893740135 @default.
• W1968882012 cites W1941332786 @default.
• W1968882012 cites W1964321121 @default.
• W1968882012 cites W1967763477 @default.
• W1968882012 cites W1971605007 @default.
• W1968882012 cites W1982729445 @default.
• W1968882012 cites W1990287461 @default.
• W1968882012 cites W2013889785 @default.
• W1968882012 cites W2020830322 @default.
• W1968882012 cites W2039140611 @default.
• W1968882012 cites W2043696829 @default.
• W1968882012 cites W2060217807 @default.
• W1968882012 cites W2072894518 @default.
• W1968882012 cites W2074440232 @default.
• W1968882012 cites W2083230165 @default.
• W1968882012 cites W2097097666 @default.
• W1968882012 cites W2101562875 @default.
• W1968882012 cites W2110835998 @default.
• W1968882012 cites W2112720107 @default.
• W1968882012 cites W2120510715 @default.
• W1968882012 cites W2127101185 @default.
• W1968882012 cites W2128307445 @default.
• W1968882012 cites W2168812605 @default.
• W1968882012 cites W2326413988 @default.
• W1968882012 cites W4293395719 @default.
• W1968882012 doi "https://doi.org/10.1016/j.urology.2006.12.003" @default.
• W1968882012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17320695" @default.
• W1968882012 hasPublicationYear "2007" @default.
• W1968882012 type Work @default.
• W1968882012 sameAs 1968882012 @default.
• W1968882012 citedByCount "46" @default.
• W1968882012 countsByYear W19688820122012 @default.
• W1968882012 countsByYear W19688820122013 @default.
• W1968882012 countsByYear W19688820122014 @default.
• W1968882012 countsByYear W19688820122015 @default.
• W1968882012 countsByYear W19688820122016 @default.
• W1968882012 countsByYear W19688820122017 @default.
• W1968882012 countsByYear W19688820122018 @default.
• W1968882012 countsByYear W19688820122019 @default.
• W1968882012 crossrefType "journal-article" @default.
• W1968882012 hasAuthorship W1968882012A5017033561 @default.
• W1968882012 hasAuthorship W1968882012A5037538728 @default.
• W1968882012 hasAuthorship W1968882012A5049429003 @default.
• W1968882012 hasAuthorship W1968882012A5079096357 @default.
• W1968882012 hasConcept C121608353 @default.
• W1968882012 hasConcept C126322002 @default.
• W1968882012 hasConcept C143998085 @default.
• W1968882012 hasConcept C2776694085 @default.
• W1968882012 hasConcept C2777329042 @default.
• W1968882012 hasConcept C2778239845 @default.
• W1968882012 hasConcept C2778820342 @default.
• W1968882012 hasConcept C2779251935 @default.
• W1968882012 hasConcept C2779786085 @default.
• W1968882012 hasConcept C2780258809 @default.
• W1968882012 hasConcept C2780352672 @default.
• W1968882012 hasConcept C502942594 @default.
• W1968882012 hasConcept C530470458 @default.
• W1968882012 hasConcept C71924100 @default.
• W1968882012 hasConcept C98274493 @default.
• W1968882012 hasConceptScore W1968882012C121608353 @default.
• W1968882012 hasConceptScore W1968882012C126322002 @default.
• W1968882012 hasConceptScore W1968882012C143998085 @default.
• W1968882012 hasConceptScore W1968882012C2776694085 @default.
• W1968882012 hasConceptScore W1968882012C2777329042 @default.
• W1968882012 hasConceptScore W1968882012C2778239845 @default.
• W1968882012 hasConceptScore W1968882012C2778820342 @default.
• W1968882012 hasConceptScore W1968882012C2779251935 @default.
• W1968882012 hasConceptScore W1968882012C2779786085 @default.
• W1968882012 hasConceptScore W1968882012C2780258809 @default.
• W1968882012 hasConceptScore W1968882012C2780352672 @default.
• W1968882012 hasConceptScore W1968882012C502942594 @default.
• W1968882012 hasConceptScore W1968882012C530470458 @default.
• W1968882012 hasConceptScore W1968882012C71924100 @default.
• W1968882012 hasConceptScore W1968882012C98274493 @default.
• W1968882012 hasIssue "2" @default.
• W1968882012 hasLocation W19688820121 @default.
• W1968882012 hasLocation W19688820122 @default.
• W1968882012 hasOpenAccess W1968882012 @default.
• W1968882012 hasPrimaryLocation W19688820121 @default.
• W1968882012 hasRelatedWork W1984065964 @default.
• W1968882012 hasRelatedWork W2048136894 @default.
• W1968882012 hasRelatedWork W2056021046 @default.
• W1968882012 hasRelatedWork W2075966869 @default.
• W1968882012 hasRelatedWork W2091157550 @default.
• W1968882012 hasRelatedWork W2115007832 @default.
• W1968882012 hasRelatedWork W2161139034 @default.
• W1968882012 hasRelatedWork W2391963389 @default.
• W1968882012 hasRelatedWork W2418580632 @default.
• W1968882012 hasRelatedWork W4224986373 @default.

• next